Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.52 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.52 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.52 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.52 |
| ▸ | CDC7 | O00311 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498618 | 0.95 | GSK3B (0.61) | GSK3BCDK1CDK2PRKAB2PRKAG1 | |
| SCHEMBL4497927 | 0.94 | GSK3B (0.57) | GSK3BCDK1CDK2PRKAB2PRKAG1 | |
| SCHEMBL4495389 | 0.92 | MAP2K4 (0.60) | GSK3BCDK1CDK2PRKAB2PRKAG1 | |
| SCHEMBL4502386 | 0.89 | GSK3B (0.57) | GSK3BCDK1CDK2PRKAB2PRKAG1 | |
| SCHEMBL4498891 | 0.89 | MAP2K4 (0.57) | GSK3BCDK1CDK2PRKAB2PRKAG1 | |
| SCHEMBL4500596 | 0.89 | GSK3B (0.53) | GSK3BCDK1CDK2PRKAB2PRKAG1 | |
| SCHEMBL4498357 | 0.89 | CDC7 (0.55) | GSK3BCDK1CDK2PRKAB2PRKAG1 | |
| SCHEMBL4491361 | 0.89 | GSK3B (0.55) | GSK3BCDK1CDK2PRKAB2PRKAG1 | |
| SCHEMBL4497718 | 0.89 | GSK3B (0.55) | GSK3BCDK1CDK2PRKAB2PRKAG1 | |
| SCHEMBL4498232 | 0.87 | GSK3B (0.53) | GSK3BCDK1CDK2PRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537087-B1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2012-11-28 | — | — | EP | claimed |
| US-7166629-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | claimed |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | AVENTIS PHARMA S.A. (FR) | 2004-06-10 | — | — | US | claimed |
| EP-1537087-B1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2012-11-28 | — | — | EP | disclosed |
| US-7582669-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA SA (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20070093479-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-7166629-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | disclosed |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | AVENTIS PHARMA S.A. (FR) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093479-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SUCNR1, CNR1, SIGMAR1 | GSK3B 3594/4885CDK1 1614/4885CDK2 2075/4885 |
| US-20040110956-A1 | 3-aminoindazole derivatives, e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; treating diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, and frontoparietal dementia | OXSR1, OXER1, OXGR1 | GSK3B 464/4885CDK1 380/4885CDK2 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.